芳香化酶抑制剂相关骨关节疼痛研究进展  

Research of aromatase inhibitor-associated arthralgia

作　　者：董欣悦[1] 方立萍[2] 蒋葵[2] 

机构地区：[1]大连医科大学研究生院第二临床学院,163000 [2]大连医科大学附属第二医院肿瘤科

出　　处：《国际肿瘤学杂志》2014年第7期536-540,共5页Journal of International Oncology

摘　　要：芳香化酶抑制剂（AI）是绝经后乳腺癌激素受体阳性患者内分泌治疗的主要药物，但其不良反应骨关节疼痛（AIA）潜在影响这类药物的临床实用。目前关于AIA的发生机制并不十分清楚，文献报道与雌激素水平下降、免疫指标异常、腱鞘变化及关节积液等有关。在临床中重视并选择适当手段治疗AIA，减少AIA的发生，有助于提高使用AI的依从性。Aromataseinhibitors（AI）aretheleadingcarefortheadjuvanttreatmentofhormone responsive carcinoma of the breast as demonstrated in a number of large international phase III randomised tri-als.Aromatase inhibitor-associated arthralgia （AIA ）was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice.The pathogenesis of AIA is not very clear currently,with the cause of most research focusing on estrogen deprivation,immune abnormalities,tenosy-novial changes and joint effusions.It is extremely urgent that we evaluate this syndrome and select appropriate therapeutic strategies to reduce the incidence of AIA,thereby improving breast cancer-related outcomes.

关 键 词：疼痛 乳腺肿瘤 芳香化酶抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]